Weight-normalized norepinephrine dosing and apparent BMI-dependent vasopressin responsiveness - Report - MDSpire

Weight-normalized norepinephrine dosing and apparent BMI-dependent vasopressin responsiveness

  • By

  • Pedro D. Wendel-Garcia

  • Sebastian Morales

  • Paulo Melo

  • Greta Emilia Kiavialaitis

  • Peter Wohlrab

  • Ricardo Castro

  • Edda Tschernko

  • Glenn Hernández

  • Eduardo Kattan

  • April 14, 2026

  • 0 min

Share

Clinical Report: Norepinephrine Dosing Adjusted for Weight and Vasopressin Responsiveness

Overview

Revise to include specific methodological biases and their clinical implications.

Background

Incorporate details on pharmacokinetics and pharmacodynamics related to norepinephrine in obese patients.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Obese patients exhibit lower baseline norepinephrine doses compared to normal-weight patients.
  • Weight-normalized norepinephrine exposure may introduce bias in assessing vasopressor responsiveness.
  • Absolute norepinephrine dosing may provide a clearer understanding of hemodynamic responses across different BMI groups.
  • Scaling norepinephrine by body weight could lead to misinterpretation of shock severity and treatment escalation.
  • Time-dependent pharmacokinetic effects may influence the observed norepinephrine trajectories in obese patients.

Clinical Implications

Clinicians should be cautious when interpreting norepinephrine dosing metrics normalized to body weight, as this may misrepresent the actual pharmacodynamic response in obese patients. Reevaluating dosing strategies and considering absolute dosing may enhance treatment efficacy and patient outcomes in septic shock management.

Conclusion

The findings underscore the need for a critical reassessment of norepinephrine dosing practices in obese patients to ensure appropriate treatment and avoid potential delays in therapeutic escalation.

References

  1. Melchers et al., Intensive Care Medicine, 2024 -- Norepinephrine Dosing Adjusted for Weight and Vasopressin Responsiveness
  2. Mastering Norepinephrine Dosing in Vasopressor Therapy: Key Insights
  3. Reduced hemodynamic response to adjunctive vasopressin in septic shock patients with obesity: a physiological or dosage-related phenomenon?
  4. Association of noradrenaline dose with mortality in critically ill patients: a systematic review and dose-response meta-analysis
  5. Examining Norepinephrine Dosage Reporting: Are We Viewing the Same Issue from Different Perspectives?

Original Source(s)

Weight-normalized norepinephrine dosing and apparent BMI-dependent vasopressin responsiveness

  • by Pedro D. Wendel-Garcia, Sebastian Morales, Paulo Melo, Greta Emilia Kiavialaitis, Peter Wohlrab, Ricardo Castro, Edda Tschernko, Glenn Hernández, Eduardo Kattan

  • April 14, 2026

Related Content

Reorienting catch-up growth research toward early-life prevention of metabolic disorders using natural products

Impact of body mass index on outcomes of cardiac rehabilitation: a systematic review and meta-analysis

The RASA2/RASA3 ortholog RasGAP1 modulates obesity-linked phenotypes and is associated with leptin-analog signaling in Drosophila